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Abst ract  Diseases in childhood 
have an impact on growth. The influ- 
ence of Langerhans cell histiocytosis 
(LCH) on growth has never been 
studied well. Recently a patient with 
LCH was treated with human growth 
hormone (GH) because of severe GH 
deficiency due to LCH involvement 
of both the hypothalamus and pitu- 
itary. This led us to review our charts 
from 1971 onward for evaluation of 
the growth patterns in patients with 
LCH. Here the long-term growth of 
22 patients with LCH is reported, the 
median follow up being 7 years and 
1 month. The height data were con- 
verted into standard eviation scores 
(SDS). At diagnosis the mean SDS 
of patients with isolated LCH at di- 
agnosis was 0.04 and -0.37 in pa- 
tients with disseminated LCH. Of the  
total group, 12 patients did not show 
any influence from the LCH or ther- 
apy on their growth. The remaining 
10 patients reached, after a minimum 
of 3 years, a percentile clearly higher 
than that at diagnosis. However all 
the ten above mentioned patients, ei- 
ther isolated or disseminated LCH, 
had a lesion in the facial side of the 
skull. 
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Introduction 
Langerhans cell histiocytosis (LCH), formerly known as 
histiocytosis X, can occur as an isolated or as a dissemi- 
nated disease. LCH can affect almost every organ and ex- 
acerbations and spontaneous remissions can occur. In 
general, isolated LCH has a benign course, while dissem- 
inated LCH is more severe and tends to be progressive 
[7]. 
Short stature in LCH is considered to be a well known 
complication [1, 10]. The incidence of short stature in 
LCH secondary to growth hormone (GH) deficiency has 
been estimated to be less than 1% [6]. 
The course of growth of children is an index for their 
health. We studied growth patterns of children with LCH. 
Factors that could influence growth of patients with LCH 
are: anterior pituitary destruction, diabetes insipidus, cata- 
bolic effects of a chronic disease, glucocorticoid therapy, 
effects of X-ray therapy given to lytic lesions of the skull, 
spine or orbits [1], or malabsorption due to gastro-intesti- 
nal lesions [9]. In our patient population, one patient de- 
veloped such a severe growth hormone (GH) deficiency 
that he was treated with human growth hormone (hGH), 
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extracted from human pituitary gland. This patient is de- 
scribed in greater detail. 
Patients and methods 
During the last 22 years (February 1971-August 1993), 26 patients 
with biopsy proven LCH were treated in the Sophia Children's 
Hospital Rotterdam. Height data were collected from the medical 
chm-t of each patient at time of diagnosis, 3-monthly during the 1 st 
year, in the following 2 years twice a year and once every year af- 
terwards. Four patients were not suitable for our study (because of 
shortage of height data in three patients and in one patient puberty 
was already started). Recurrence of LCH or onset of the pubertal 
growth spurt was considered to be a cut-off point. 
In order to compare height data of patients who differ in age 
and/or sex the height data were converted into Standard Deviation 
Scores (SDS = Z-score). SDS is the difference between the pa- 
tient's height (X) and the age- and sex- appropriate population 
mean height (Y) divided by the standard eviation of the popula- 
tion mean (SDS = X-Y/SD). 
When a patient is taller than average for comparable age and 
sex the SDS is positive. (For example, the matching SDS for the 
97th percentile is 1.88.). To study the course of the growth every 
SDS has been subtracted from the SDS at diagnosis. The found 
value is called the delta SDS. Growth along the percentile results 
in a delta SDS equal to zero. 
If one organ system (bone, lymph nodes or skin) is involved, 
LCH is considered isolated, in disseminated LCH, two or more or- 
gan systems are affected. In our institution patients with dissemi- 
nated LCH were treated with chemotherapy (a combination of vin- 
blastine, prednisone, mercaptopurine and methotrexate) for a pe- 
riod of 60 weeks. Children with isolated LCH were followed or 
treated locally. Only in cases of polyostotic LCH or progression of 
the disease chemotherapy was given. 
Case report 
After a 2-month istory of diabetes insipidus, a3-year-old boy was 
admitted to the Sophia Children's Hospital of Rotterdam because 
of complaints of fainting and progression of his disease. X-ray of 
the skull showed two clear osteolytic lesions, left parietal and dor- 
sal, which after biopsy proved to be LCH. Lesions were also seen 
in the soft tissue near the pituitary gland. The diabetes insipidus was 
treated with 2 • 0.05 mg desmopressin (DDAVP) per day. On ac- 
count of the benign course of the LCH only regular attendance in the 
outpatient department was indicated. During the first 3 years of fol- 
low up, progressive r duction of his growth velocity occurred (Fig. 
la). At 7 years of age his height was 110.0 cm (3rd percentile). GH 
provocation tests with L-dopa/propranolol and clonidine revealed 
GH deficiency. Subsequently GH substitution was started with in- 
tra-muscular injections of hGH twice a week. Two years later hor- 
mone substitution therapy was ceased because of the implication 
that hGH substitution can lead to the transmission of Creutzfeldt- 
Jakob disease [4, 11]. In the pre-treatment year the patient grew 
3.4 cm, in the 1st year of therapy 10 cm and in the 2nd year 8 cm. 
After these 2 years his height was between the 3rd and the 10th 
percentile. In the 1st year thereafter he grew 6.5 cm, which is an 
accelerated growth velocity for children in the Netherlands [14] 
and GH provocation tests showed no abnormalities. The onset of 
puberty was not delayed and at the end of observation, when the 
patient was 15 years old, his height was 171 cm, which is on the 
50th percentile. There has been no evidence of other manifesta- 
tions of LCH over the total follow up period. 
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Fig. 1 a The delta SDS curve of the patient with LCH and GH de- 
ficiency. The period of hGH substitution is indicated, b The mean 
delta SDS curve of patients with isolated LCH (above) and of pa- 
tients with disseminated LCH 
Results 
The 22 available patients consisted of 11 boys (mean age 
2 years and 1 month) and 11 girls (mean age 3 years and 
6 months). Eleven patients had disseminated LCH (mean 
age 1 year and 10 months, median fol low up 7 years and 
2 months) and 11 patients had isolated LCH (mean age 3 
years and 9 months, median fol low-up 6 years and 2 
months) [see Table 1]. 
The mean SDS at time of diagnosis for patients with 
isolated LCH was 0.04, whereas the mean SDS at time of 
diagnosis for patients with disseminated LCH was -0.37. 
Figure lb shows mean delta SDS-curves of patients with 
isolated LCH and disseminated LCH; by definition the 
delta SDS at time of diagnosis is 0. During the first 6 
months after diagnosis the mean delta SDS decreased. In 
the group of patients with disseminated LCH this decrease 
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Table 1 Incidence of organ involvement for the 22 patients with 
LCH 
Localized Disseminated 
(n = 11) (n = 11) 
Bone lesions 9 (82%) 10 (91%) 
Skin lesions 2 (18%) 6 (55%) 
Hepatomegaly - 3 (27%) 
Splenomegaly - 2 (18%) 
Pulmonary lesions - 3 (27%) 
Lymphadenomegaly - 4 (36%) 
Diabetes insipidus - 2 (18%) 
was more clear. In the following 18 months the mean 
delta SDS increased to zero, this is catch-up growth. In 
the period from 2 years after the diagnosis until the end 
of the observation period (8 years after diagnosis) mean 
delta SDS was above zero and is considered overshoot. 
Thirteen patients were treated with the mentioned 
chemotherapeutic regimen, including 4 patients with poly- 
ostotic localized disease or with progression of their lo- 
calized LCH. Two of these 13 received additional radio- 
therapy. Four patients were treated with radiotherapy 
only. The remaining 5 patients were diagnosed either with 
surgery or biopsy and were observed. 
Discussion 
Literature on long-term growth patterns of children with 
LCH is scarce. In 22 patients with biopsy proven LCH 
Dean et al. [6] observed 1 patient, who had received 30 
Gy irradiation directly to the hypothalamic-pituitary ea, 
with clinical and biochemical evidence of GH deficiency. 
GH provocation tests were done in 11 more patients. De- 
spite normal stature and growth velocity three patients 
(all with diabetes insipidus) showed subnormal GH re- 
sponses. Their growth rates, however, continued to be 
normal over 6 to 14 years of follow up. The authors con- 
cluded that true growth failure only occurred in asso- 
ciation with a direct hypothalamic-pituitary irradiation. 
Braunstein et al. [2] reported the response of five patients 
with Hand-Schtiller-Christian disease to hGH therapy. In 
this study the mean growth rate was 7.5 cm in the 1st year 
of therapy and 5.1cln in the following year. In the pre- 
treatment year the mean growth rate was 2.3 cm. In this 
study the patients treated with hGH responded well [2]. In 
a report by Latorre et al. in 1974 [10], 13 children with 
LCH documented by biopsy were studied. All but one of 
the children had multisystem involvement and slow, 
chronic, clinical courses. Ten children had had clinical 
disease in excess of 8 years at the time of endocrine val- 
uation, one child for 5 years, and two children for 2 years. 
Evidence of diabetes insipidus was one of the initial com- 
plaints of four children and was manifest in 9 of 13 at the 
time of this study. Of the 13 patients, 8 were at or below 
the 3rd percentile for height, 3 were at the 10th percentile, 
and 1 patient, although above the 50th percentile for 
height at the time of study, had suffered sustained marked 
reduction in growth rate during the previous years. Evi- 
dence for suboptimal growth was present in 12 of the pa- 
tients. Diabetes insipidus and/or GH deficiency was pre- 
sent in ten patients [10]. Eosinophilic granuloma in a ver- 
tebra, causing vertebra plana, has only a minor influence 
on final length as the collapsed vertebra reaches at least 
80% of the height of the adjoining vertebra fter recovery 
[12]. This sequelae will only lead to a decrease of length 
of a few centimetres if more than one vertebrae are af- 
fected. 
Two of our patients were suspected to have GH defi- 
ciency. GH provocation tests revealed that one patient had 
developed GH deficieny as a complication of LCH. This 
patient was treated with hGH for 2 years and responded 
well. After ceasing the therapy, the GH provocation tests 
showed no abnormalities. The patient continued to grow 
at an accelerated rate and consequently reached the 50th 
percentile. It is known that spontaneous remissions can 
occur in LCH [3, 5]. A spontaneous remission of the LCH 
lesion in the pituitary gland and/or hypothalamus can be 
the explanation in our patient for his normal provocation 
tests and accelerated growth after ceasing the hGH therapy. 
This accelerated growth velocity could indicate that growth 
velocity was already lowered before primary diagnosis. 
Although a small group the incidence of affected or- 
gans of our patients with disseminated LCH is compa- 
rable to the literature [7]. The delta SDS curves of the 
group of patients with isolated versus disseminated LCH 
(Fig. lb) show a similar course. However, in the post diag- 
nosis period the SDS of patients with disseminated LCH 
becomes more negative. The explanation for this larger 
reduction in growth velocity can be that patients with dis- 
seminated LCH are more severely affected and accord- 
ingly, therapy is more aggressive. In spite of continuation 
of therapy, the catch-up growth begins 6 months after di- 
agnosis. Two years after diagnosis the delta SDS becomes 
positive until the end of observation. This overshoot could 
be explained by assuming that reduction in growth veloc- 
ity could have appeared before the diagnosis is made. 
Thus in reality this overshoot may be a return to the initial 
percentile. 
The delta SDS curve of patients treated with chemo- 
therapy is comparable with delta SDS curves of patients 
with (non high-risk) acute lymphoblastic leukaemia treated 
with chemotherapy without radiation therapy [8]. How- 
ever in these patients the delta SDS diverges to zero after 
5-6 years of overshoot. Craniospinal radiation of 24 Gy 
or more can cause reduction of GH secretion [8, 13]. In 
our group one patient received 24 Gy to the pituitary 
gland region, but did not develop GH deficiency. 
It is striking that ten patients did reach a percentile 
clearly higher than their percentile at diagnosis. All had 
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one or more lesions on the facial side of the skull. An  ex- 
planation for this phenomenon remains uncertain, but one 
can speculate that the GH release of the pituitary gland is 
elevated after recovery of  the LCH, or decreased before 
LCH is diagnosed. No data of height were avai lable be- 
fore the diagnosis of LCH was made. 
In summary, GH deficiency is not a common manifes- 
tation of LCH in chi ldhood and GH provocat ion tests are 
only indicated when there is a poor or decelerating growth 
rate. Height of LCH patients at diagnosis does not differ 
from the average height of a healthy population. We found 
that no growth retardation occurred under influence of  the 
number of organs involved and/or therapy in all patients 
but one. 
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